Last reviewed · How we verify
Placebo to Evolocumab
Placebo to Evolocumab is a PCSK9 inhibitor Small molecule drug developed by Amgen. It is currently in Phase 3 development for Hypercholesterolemia, Heterozygous familial hypercholesterolemia.
Evolocumab works by binding to PCSK9, a protein that regulates cholesterol levels in the blood, thereby increasing the levels of HDL and reducing the levels of LDL.
Evolocumab works by binding to PCSK9, a protein that regulates cholesterol levels in the blood, thereby increasing the levels of HDL and reducing the levels of LDL. Used for Hypercholesterolemia, Heterozygous familial hypercholesterolemia.
At a glance
| Generic name | Placebo to Evolocumab |
|---|---|
| Sponsor | Amgen |
| Drug class | PCSK9 inhibitor |
| Target | PCSK9 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
By inhibiting PCSK9, evolocumab increases the number of LDL receptors on the liver, allowing for more LDL to be removed from the blood. This results in a decrease in LDL cholesterol levels, which can help to reduce the risk of cardiovascular events.
Approved indications
- Hypercholesterolemia
- Heterozygous familial hypercholesterolemia
Common side effects
- Injection site reactions
- Musculoskeletal pain
- Diarrhea
- Nausea
- Fatigue
Key clinical trials
- Mechanistic Clinical Trial of PCSK9 Inhibition for AAA (EARLY_PHASE1)
- Chinese Herbal Therapy (Qiqi Shengmai Formula) for Moyamoya Vasculopathy: The CHIMES Trial (PHASE1)
- Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke (PHASE3)
- Effect of Evolocumab on Saphenous Vein Graft Patency Following Coronary Artery Bypass Surgery (PHASE4)
- A Research Study Looking at How NNC0385-0434 Tablets Work to Lower Blood Cholesterol in People With Heart Disease or a High Risk of Heart Disease (PHASE2)
- Functional Improvement of Coronary Artery Narrowing by Cholesterol Reduction With a PCSK9 Antibody (NA)
- Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (PHASE3)
- Pharmacodynamic Biomarkers to Support Biosimilar Development: PCSK9 Inhibitors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo to Evolocumab CI brief — competitive landscape report
- Placebo to Evolocumab updates RSS · CI watch RSS
- Amgen portfolio CI
Frequently asked questions about Placebo to Evolocumab
What is Placebo to Evolocumab?
How does Placebo to Evolocumab work?
What is Placebo to Evolocumab used for?
Who makes Placebo to Evolocumab?
What drug class is Placebo to Evolocumab in?
What development phase is Placebo to Evolocumab in?
What are the side effects of Placebo to Evolocumab?
What does Placebo to Evolocumab target?
Related
- Drug class: All PCSK9 inhibitor drugs
- Target: All drugs targeting PCSK9
- Manufacturer: Amgen — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Hypercholesterolemia
- Indication: Drugs for Heterozygous familial hypercholesterolemia
- Compare: Placebo to Evolocumab vs similar drugs
- Pricing: Placebo to Evolocumab cost, discount & access